GPS Vaccine Plus Opdivo Shows Promise for Pleural Mesothelioma
A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer responds to standard chemotherapy. In a phase I clinical trial at Memorial Sloan Kettering Cancer Center, the galinpepimut-S vaccine, also known as GPS, has produced an impressive, anti-tumor synergy with Opdivo, based upon early data. GPS targets the WT1 protein, which is expressed in high levels of various cancers but rarely seen in normal adult cells. The protein has been especially resistant to standard chemotherapy. The vaccine works by inducing a powerfu...
Source: Asbestos and Mesothelioma News - June 29, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mayo Clinic Opens Novel Clinical Trial for Mesothelioma
Researchers at the much-acclaimed Mayo Clinic in Rochester, Minnesota, have opened the first clinical trial for mesothelioma patients that combines a recently approved immunotherapy treatment with targeted radiation. Potential for extending survival is there. This single-center phase I clinical trial opens June 24, and is expected to enroll at least 20 participants. It will study the safety and effectiveness of stereotactic body radiation therapy, known as SBRT, when added to the immunotherapy combination of Opdivo and Yervoy. “The reasoning behind this study is that we need to build upon the success we’ve see...
Source: Asbestos and Mesothelioma News - June 23, 2021 Category: Environmental Health Authors: Lynette Zilio Source Type: news

Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma
Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He was the lead investigator in a recent phase II clinical trial studying the efficacy of vinorelbine for patients whose pleural mesothelioma cancer had progressed after traditional platinum-based chemotherapy. Fennell, who is chair of thoracic and medical oncology at University of Leicester and University Hospitals in the United Kingdom, has based his belief on the multicenter trial involving 154 mesothelioma patients with relapsed disease. “Doctors should now feel...
Source: Asbestos and Mesothelioma News - June 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

ONCOS-102 Vaccine Showing Impressive Results for Mesothelioma
The novel immunotherapy vaccine ONCOS-102 may become the answer for the large percentage of mesothelioma cancer patients who fail to respond to a recently approved checkpoint inhibitor combination of treatment. ONCOS-102, a genetically modified oncolytic adenovirus, showed an overall survival rate of between 21.9 and 25 months in a randomized phase II clinical trial when combined with standard chemotherapy in a first-line setting. By comparison, patients in the trial receiving only standard chemotherapy had a median survival of just 13.5 months. The vaccine is the lead product of Targovax, a small Scandinavian bio...
Source: Asbestos and Mesothelioma News - June 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Breath Test Predicts Immunotherapy Response to Mesothelioma
Researchers in the Netherlands are touting a novel breath test for mesothelioma patients to better predict response to the immunotherapy combination of nivolumab and ipilimumab that was approved recently for first-line treatment of the disease. They believe exhaled breath analysis using electronic technology – known as eNose – can differentiate between responders and nonresponders before treatment begins, saving many patients from unnecessary side effects. There currently are no biomarkers for mesothelioma that can accurately predict the effectiveness of these types of immunotherapy drugs, known as immune checkpo...
Source: Asbestos and Mesothelioma News - June 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

EPA Agrees to Address Asbestos Data-Collection Deficiencies
Under pressure from a multistate coalition, the U.S. Environmental Protection Agency has agreed to tighten its data collection process for asbestos, moving the country another step closer to banning the toxic substance. The agreement comes six months after a U.S. District Court judge in California ruled the EPA must improve its ineffective data collection on asbestos imports, and two years after attorneys general in multiple states challenged in court the EPA’s lack of more restrictive asbestos regulations. “The longtime failure of the EPA to regulate asbestos is an environmental injustice and public health trage...
Source: Asbestos and Mesothelioma News - June 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU
Nivolumab plus ipilimumab showed superior overall survival versus standard-of-care chemotherapy in patients with unresectable malignant mesothelioma.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

U.S. Supreme Court Rejects J & J Appeal of $2 Billion Talc Verdict
The U.S. Supreme Court rejected a request June 1 from Johnson & Johnson to consider overturning a $2.1 billion award to 22 women who blamed the company’s asbestos-contaminated talcum powder products for causing ovarian cancer. With the Supreme Court declining to consider it, a Missouri state court ruling from 2018 that originally awarded $4.69 billion remains in place. A Missouri court of appeals reduced the award in 2020 to $2.1 billion, but also rejected a J&J effort to dismiss the jury verdict. The appeal did not involve the question of whether the products caused cancer. Johnson & Johnson wanted the...
Source: Asbestos and Mesothelioma News - June 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Memorial Sloan Kettering Opening New Mesothelioma Clinical Trial
Memorial Sloan Kettering Cancer Center in New York City will begin recruiting soon for its latest clinical trial involving patients with malignant pleural mesothelioma and the expanded use of immunotherapy. The single-center, phase I study will explore the effectiveness of pembrolizumab in combination with intensity-modulated pleural radiation therapy, known as IMPRINT, in treating unresectable disease. Pembrolizumab, also known by the brand name Keytruda, was approved by the U.S. Food and Drug Administration in 2020 for treatment of a small subset of mesothelioma patients. As a well-known immunotherapy drug, pemb...
Source: Asbestos and Mesothelioma News - May 26, 2021 Category: Environmental Health Authors: Matt Bardsley Source Type: news

MD Anderson Examines Aggressive Mesothelioma Surgery in Latest Study
A retrospective study involving two decades of pleural mesothelioma patients at the heralded University of Texas MD Anderson Cancer Center failed to demonstrate a definitive survival advantage to support regular use of extrapleural pneumonectomy surgery. The most aggressive surgery possible for this type of mesothelioma – once the surgery of choice – showed no clear benefit over a more conservative procedure. When compared to the less-aggressive, lung-sparing pleurectomy and decortication surgery, EPP had a much higher perioperative mortality rate and a shorter median survival. “In comparison, we have not be...
Source: Asbestos and Mesothelioma News - May 25, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Faulty Gene Could Raise Vulnerability to Asbestos-Linked Cancer
FRIDAY, May 21, 2021 -- Mutations in a certain gene may increase a person ' s risk for an aggressive asbestos-related cancer called malignant mesothelioma, a new study claims. The gene is called LRRK2 and is involved in regulating responses in immune... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 21, 2021 Category: General Medicine Source Type: news

EPA Facing More Litigation on Legacy Asbestos
The Asbestos Disease Awareness Organization delivered on an earlier notice of intent to sue by filing an official complaint against the U.S. Environmental Protection Agency over its ongoing risk evaluation of asbestos. ADAO, a leading nonprofit aimed at preventing asbestos exposure, was joined by five other organizations and several public health experts in asking the court to set a deadline for the EPA to complete its work. The lawsuit was filed May 18 in the U.S. Northern District of California Court in San Francisco. The notice of intent to sue  was delivered in January. Thoracic surgeon Dr. Raja Flores of Mo...
Source: Asbestos and Mesothelioma News - May 20, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

A Look at Three Decades of Real-World Mesothelioma Statistics
Despite clinical trials that often produce inflated expectations, real-world survival rates for pleural mesothelioma have failed to advance significantly over the past three decades, according to one recent study in Canada. Celebrated treatment advances have fallen short for the average patient diagnosed with this rare cancer caused by exposure to asbestos. “This is a story about a lack of progress. What we’ve seen is kind of underwhelming,” Dr. Paul Wheatley-Price, associate professor of medicine at University of Ottawa and thoracic oncologist at The Ottawa Hospital Cancer Centre, told The Mesothelioma Center ...
Source: Asbestos and Mesothelioma News - May 11, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Asbestos-Contaminated Talc Central to Old Spice Mesothelioma Lawsuit
Willie McNeal Jr., a Vietnam War veteran and retired school bus driver, was awarded $4.8 million by a California Superior Court jury that determined asbestos-contaminated talc led to his diagnosis of malignant pleural mesothelioma. Whittaker, Clark & Daniels, a longtime talc supplier now based in South Plainfield, New Jersey, was ordered to pay McNeal $1.8 million in compensatory damages and $3 million in punitive damages. The verdict stemmed from evidence presented that an Old Spice powder product, used almost daily by McNeal for more than 20 years, contained talc from a mine in North Carolina known to be contam...
Source: Asbestos and Mesothelioma News - May 6, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Canada Moves Toward Increased Talc Restrictions
Canada may soon become the first country to legally restrict the use of popular talc-based products, stemming from an extensive, recently completed human health assessment of the naturally occurring mineral. Health Canada, the governmental agency responsible for national health policy, issued an official advisory in April, concluding that loose talc products – such as body powder, baby powder and genital deodorants – can cause serious lung problems and ovarian cancer. The agency has proposed expanded restrictions on the use of talc in cosmetics, natural health products and nonprescription drugs that can be inhale...
Source: Asbestos and Mesothelioma News - May 4, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news